Literature DB >> 11594526

Acquired storage-pool disorders occurring late after allogeneic bone marrow transplantation: partial activation of platelets in asymptomatic patients.

C Sakashita1, H Akiyama, Y Satoh, T Inoue, K Ohashi, S Mori, H Sakamaki, K Hiruma, M Endoh, N Akamatsu, K Tanoue.   

Abstract

Bone marrow transplantation (BMT) may be complicated by coagulation abnormalities. The present study evaluated whether platelets might be activated in patients who had undergone BMT without significant coagulopathy. The patients selected had received allogeneic BMTs a median of 39 months before the study (range, 11-124 months) and had not received cyclosporine, FK506 (tacrolimus), or other medication affecting cyclo-oxygenase for at least 3 months prior to the collection of blood samples. Furthermore, patients had platelet counts greater than 100 x 10(9) cells/L and normal serum creatinine levels. Twenty-five healthy volunteers acted as controls. Platelet aggregation studies and a mepacrine assay of platelets showed abnormal aggregation and decreased staining in some patients. The platelet storage-pool adenosine 5'-triphosphate (ATP) level in 15 patients after BMT was 0.45+/-0.24 micromol per 10(11) platelets, whereas the level in 18 controls was 1.03+/-0.36 micromol per 10(11) platelets (P = .00078). The total ATP levels of platelets in patients and controls were 4.33+/-1.14 and 5.63+/-1.51 micromol per 10(11) platelets, respectively (P = .016). With the exception of 1 patient, plasma levels of thrombomodulin and von Willebrand factor were all within the normal range. The average plasma level of 11-dehydrothromboxane B2 was significantly increased in 15 patients after BMT compared with controls, 20.6+/-8.2 and 10.3+/-1.2 pg/mL, respectively (P = .0004). These findings suggest a long-term process of platelet activation in patients after BMT and, following the cessation of cyclosporine, development of acquired storage-pool disorder of platelets.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594526     DOI: 10.1007/bf02982009

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

1.  Microangiopathy without hemolysis in a patient following allogeneic bone marrow transplantation.

Authors:  H Akiyama; H Yoshinaga; M Endou; S Tanikawa; H Sakamaki; K Tanoue; Y Onozawa
Journal:  Bone Marrow Transplant       Date:  1997-08       Impact factor: 5.483

Review 2.  Flow cytometry: a clinical test of platelet function.

Authors:  A D Michelson
Journal:  Blood       Date:  1996-06-15       Impact factor: 22.113

3.  Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation.

Authors:  S Testa; A Manna; A Porcellini; F Maffi; G Morstabilini; N Denti; S Macchi; G Rosti; G Porcellini; D Cassi; L Ferrari
Journal:  Bone Marrow Transplant       Date:  1996-08       Impact factor: 5.483

Review 4.  Pathophysiology and treatment of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).

Authors:  E Kakishita
Journal:  Int J Hematol       Date:  2000-06       Impact factor: 2.490

5.  Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease.

Authors:  C Salat; E Holler; H J Kolb; R Pihusch; B Reinhardt; E Hiller
Journal:  Bone Marrow Transplant       Date:  1997-05       Impact factor: 5.483

6.  Endothelium and bone marrow transplantation.

Authors:  L Catani; L Gugliotta; N Vianelli; F Nocentini; S Baravelli; G Bandini; T M Cirio; S Tura
Journal:  Bone Marrow Transplant       Date:  1996-02       Impact factor: 5.483

Review 7.  Thrombotic microangiopathy following bone marrow transplantation.

Authors:  A R Pettitt; R E Clark
Journal:  Bone Marrow Transplant       Date:  1994-10       Impact factor: 5.483

8.  11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation.

Authors:  F Catella; D Healy; J A Lawson; G A FitzGerald
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

9.  von Willebrand factor as a marker of endothelial cell activation following BMT.

Authors:  P W Collins; C N Gutteridge; A O'Driscoll; S Blair; L Jones; R Aitchison; S M Kelsey; R Chopra; A Goldstone; A C Newland
Journal:  Bone Marrow Transplant       Date:  1992-12       Impact factor: 5.483

10.  Identification of 11-dehydro-TXB2 as a suitable parameter for monitoring thromboxane production in the human.

Authors:  P Westlund; E Granström; M Kumlin; A Nordenström
Journal:  Prostaglandins       Date:  1986-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.